{"id":"tucatinib-plus-trastuzumab-subcutaneous-sc","_chembl":{"chemblId":"CHEMBL3989868","moleculeType":"Small molecule","molecularWeight":"480.53"},"allNames":"tucatinib plus trastuzumab subcutaneous (sc)","_dailymed":null,"mechanism":{"target":"HER2","drugClass":"HER2 inhibitor","explanation":"This combination therapy works by using tucatinib to block the HER2 protein, which is overexpressed in some breast cancers, while trastuzumab binds to HER2 on the surface of cancer cells, marking them for destruction by the immune system.","oneSentence":"Tucatinib plus Trastuzumab SC targets HER2-positive breast cancer cells, inhibiting HER2 signaling and promoting antibody-dependent cell-mediated cytotoxicity."},"_scrapedAt":"2026-03-28T01:47:38.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:45:41.317717+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT05583110","phase":"PHASE2","title":"Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-03-08","conditions":"HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma","enrollment":13},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT05091528","phase":"PHASE1, PHASE2","title":"A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers","status":"TERMINATED","sponsor":"Silverback Therapeutics","startDate":"2022-02-08","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Tucatinib plus Trastuzumab Subcutaneous (SC)","genericName":"tucatinib-plus-trastuzumab-subcutaneous-sc","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":9,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:45:41.317717+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}